Dr. Janet Dancey is the leader of the High Impact Clinical Trials program at OICR and the Director of the NCIC Clinical Trials Group. The High Impact Clinical Trials program will facilitate the translation of discoveries from laboratory to clinic by providing infrastructure and resources to support trials evaluating markers for early diagnosis, prognosis, and predication of benefit to help develop better treatments for cancer patients.
|2014 -||Director, NCIC Clinical Trials Group.|
|2013 -||Scientific Director, Canadian Cancer Clinical Trials Network (3CTN).|
|2008 -||Professor, Department of Oncology, Queen's University.|
|2008 -||Program Director, High Impact Clinical Trials, Ontario Institute for Cancer Research (OICR).|
|2008 -||Chair, Experimental Therapeutics Network, Cancer Care Ontario (CCO).|
Dancey J. Early Clinical Trial Design Issues: Patient Populations, Endpoints and Barriers. In: Pandya KJ, Brahmer J, Hidalgo M, editors. Lung Cancer: Translational and Emerging Therapies. New York: Taylor & Francis Group, LLC; 2007.
- Dancey J and Chen H
Strategies for optimizing combinations of molecularly targeted anticancer agents
- Nature Reviews Drug Discovery. 5:649-59; 2006
- Dancey JE
Predictive Factors for Epidermal Growth Factor Receptor Inhibitors – The Bull’s-Eye Hits the Arrow
- Cancer Cell. 5:411-5; 2004
- Dancey J and Sausville E
Issues And Progress With Protein Kinase Inhibitors For Cancer Treatment
- Nat Rev Drug Discov. 2:296-313; 2003
- Dancey J, Freidlin B
Agents Targeting EGFR: Are We Missing the Mark?
- Lancet. 362:62-4; 2003